PATH's work in Senegal

A catalyst for global health

We envision a Senegal where health is within reach for everyone

PATH opened a project office in Senegal in 2001 with the start-up of the Children’s Vaccine Program. We currently have a robust portfolio of projects in Senegal that range from a clinical trial evaluating the effectiveness of seasonal influenza vaccine to the evaluation of HIV risk reduction and behavior change interventions among at-risk populations. PATH’s areas of expertise in Senegal revolve around four main pillars: reducing the burden of infectious diseases, health system strengthening, family planning, and community empowerment.

Reducing the burden of infectious diseases

PATH focuses on three infectious diseases in Senegal: malaria, seasonal influenza, and HIV.

The Malaria Control Evaluation Partnership (MACEPA), a program at PATH that is supported in Senegal by the National Malaria Control Program, was one of the first to develop a third-generation strategic plan taking malaria control beyond scale-up and bednets toward universal coverage and actively working toward malaria elimination.

The PATH Malaria Vaccine Initiative (MVI) is a program established in 1999 through a grant from the Bill & Melinda Gates Foundation. MVI’s mission is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.

PATH has partnered with the French Institut de Recherche pour le Développement and the Institut Pasteur de Dakar (Senegal’s National Influenza Center) to lead trials of new influenza vaccines in Senegal to generate data for public health decision-makers in tropical developing Africa.

PATH is also working with the Laboratory of Bacteriology and Virology/Université Cheikh Anta Diop and Westat to implement an evidence-based HIV prevention community intervention program known as Community Peers Reaching Out and Modeling Intervention Strategies (Community PROMISE). The program targets the female sex worker population to reduce the spread of HIV and other sexually transmitted infections within the context of sex work in the Dakar region.

Health system strengthening

Project Optimize was a five-year partnership between the World Health Organization and PATH to identify ways in which supply chains can be optimized to meet the demands of an increasingly large and costly portfolio of vaccines. In Senegal, Optimize collaborated with the Senegal Ministry of Health to demonstrate innovations in the supply chain that can help the national immunization program. Senegal was one of four collaborating countries for this demonstration work.

Global Good, an entity focused on creating appropriate health technologies for the developing world, has developed a portable passive vaccine storage device that houses five liters of vaccines and with insertion of preconditioned ice blocks can maintain 0ºC to 8ºC temperature for at least 30 days in high ambient temperatures. PATH is collaborating with Global Good and the Senegal Ministry of Health to evaluate the performance, cost, and usability of this device in real clinical scenarios in Senegal to move toward World Health Organization approval.

Under a US Agency for International Development (USAID) grant for health system strengthening, PATH is working closely with ABT Associates, USAID, and Pharmacie National d’Approvisionnement (PNA) to strengthen Senegal’s logistics systems, which are critical to the success of health systems performance. PATH is building the capacities of the PNA by producing a procurement and supply manual as well as by updating the existing internal information system from the center out to the regional pharmacies.

Family planning

PATH partners with the public and private sectors to improve the health of women and children and increase access to reproductive health services. PATH worked with the Senegal Ministry of Health to identify groups who may benefit from public-sector distribution of family planning services. We also work with nongovernmental organizations and civil-society partners to ensure modern contraceptive options are available to women throughout Senegal.

Since January 2013, PATH is also leading the introduction of Sayana® Press, a novel subcutaneous contraceptive offering three months of protection. The project aims to make Sayana Press available through normal delivery channels in five countries, including Senegal, and build the evidence base for decision-making about whether and how countries can include Sayana Press in family planning programs in the future.

PATH also coordinates the regional activities of a coalition known as Sécurité Contraceptive en Afrique Francophone (SECONAF). This forum was established to support the sharing of best practices around reproductive health commodity security in Francophone Africa.

Community empowerment

PATH is leading a four-year longitudinal impact evaluation of Tostan’s Community Empowerment Program in collaboration with local research agency Centre de Recherche et Développement Humain. The study will include double baseline and endline data collection rounds from a random sample of 55 intervention villages in the Tambacounda region in the department of Goudiry of northeast Senegal. Tostan’s program includes elements of life skills and health and human rights education, as well as a newly integrated module focusing on gender.

 

Sayana Press is a registered trademark of Pfizer, Inc.

Comments are closed.